1
|
Sturaro C, Ruzza C, Ferrari F, Pola P, Argentieri M, Frezza A, Marzola E, Bettegazzi B, Cattaneo S, Pietra C, Malfacini D, Calò G. In vitro pharmacological characterization of growth hormone secretagogue receptor ligands using the dynamic mass redistribution and calcium mobilization assays. Eur J Pharmacol 2024; 981:176880. [PMID: 39128804 DOI: 10.1016/j.ejphar.2024.176880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2024] [Revised: 07/25/2024] [Accepted: 08/08/2024] [Indexed: 08/13/2024]
Abstract
Ghrelin modulates several biological functions via selective activation of the growth hormone secretagogue receptor (GHSR). GHSR agonists may be useful for the treatment of anorexia and cachexia, while antagonists and inverse agonists may represent new drugs for the treatment of metabolic and substance use disorders. Thus, the identification and pharmacodynamic characterization of new GHSR ligands is of high interest. In the present work the label-free dynamic mass redistribution (DMR) assay has been used to evaluate the pharmacological activity of a panel of GHSR ligands. This includes the endogenous peptides ghrelin, desacyl-ghrelin and LEAP2(1-14). Among synthetic compounds, the agonists anamorelin and HM01, the antagonists HM04 and YIL-781, and the inverse agonist PF-05190457 have been tested, together with HM03, R011, and H1498 from patent literature. The DMR results have been compared to those obtained in parallel experiments with the calcium mobilization assay. Ghrelin, anamorelin, HM01, and HM03 behaved as potent full GHSR agonists. YIL-781 behaved as a partial GHSR agonist and R011 as antagonist in both the assays. LEAP2(1-14) resulted a GHSR inverse agonist in DMR but not in calcium mobilization assay. PF-05190457, HM04, and H1498 behaved as GHSR inverse agonists in DMR experiments, while they acted as antagonists in calcium mobilization studies. In conclusion, this study provided a systematic pharmacodynamic characterization of several GHSR ligands in two different pharmacological assays. It demonstrated that the DMR assay can be successfully used particularly to discriminate between antagonists and inverse agonists. This study may be useful for the selection of the most appropriate compounds to be used in future studies.
Collapse
Affiliation(s)
- Chiara Sturaro
- U.O. Neurological Clinic of the University Hospital of Ferrara, Italy
| | - Chiara Ruzza
- Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy; LTTA Laboratory for Advanced Therapies, Technopole of Ferrara, Ferrara, Italy.
| | - Federica Ferrari
- Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy
| | - Pietro Pola
- Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy
| | - Michela Argentieri
- Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy
| | - Alessia Frezza
- U.O. Neurological Clinic of the University Hospital of Ferrara, Italy
| | - Erika Marzola
- Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italy
| | | | | | | | - Davide Malfacini
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Italy
| | - Girolamo Calò
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Italy
| |
Collapse
|
2
|
Piper NBC, Whitfield EA, Stewart GD, Xu X, Furness SGB. Targeting appetite and satiety in diabetes and obesity, via G protein-coupled receptors. Biochem Pharmacol 2022; 202:115115. [PMID: 35671790 DOI: 10.1016/j.bcp.2022.115115] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Revised: 05/26/2022] [Accepted: 05/27/2022] [Indexed: 11/17/2022]
Abstract
Type 2 diabetes and obesity have reached pandemic proportions throughout the world, so much so that the World Health Organisation coined the term "Globesity" to help encapsulate the magnitude of the problem. G protein-coupled receptors (GPCRs) are highly tractable drug targets due to their wide involvement in all aspects of physiology and pathophysiology, indeed, GPCRs are the targets of approximately 30% of the currently approved drugs. GPCRs are also broadly involved in key physiologies that underlie type 2 diabetes and obesity including feeding reward, appetite and satiety, regulation of blood glucose levels, energy homeostasis and adipose function. Despite this, only two GPCRs are the target of approved pharmaceuticals for treatment of type 2 diabetes and obesity. In this review we discuss the role of these, and select other candidate GPCRs, involved in various facets of type 2 diabetic or obese pathophysiology, how they might be targeted and the potential reasons why pharmaceuticals against these targets have not progressed to clinical use. Finally, we provide a perspective on the current development pipeline of anti-obesity drugs that target GPCRs.
Collapse
Affiliation(s)
- Noah B C Piper
- Receptor Transducer Coupling Laboratory, School of Biomedical Sciences, Faculty of Medicine, University of Queensland, St. Lucia, QLD 4072, Australia
| | - Emily A Whitfield
- Receptor Transducer Coupling Laboratory, School of Biomedical Sciences, Faculty of Medicine, University of Queensland, St. Lucia, QLD 4072, Australia
| | - Gregory D Stewart
- Drug Discovery Biology Laboratory, Monash Institute of Pharmaceutical Sciences & Department of Pharmacology Monash University, Parkville, VIC 3052, Australia
| | - Xiaomeng Xu
- Drug Discovery Biology Laboratory, Monash Institute of Pharmaceutical Sciences & Department of Pharmacology Monash University, Parkville, VIC 3052, Australia
| | - Sebastian G B Furness
- Receptor Transducer Coupling Laboratory, School of Biomedical Sciences, Faculty of Medicine, University of Queensland, St. Lucia, QLD 4072, Australia; Drug Discovery Biology Laboratory, Monash Institute of Pharmaceutical Sciences & Department of Pharmacology Monash University, Parkville, VIC 3052, Australia.
| |
Collapse
|
3
|
Danila GM, Puiu M, Zamfir LG, Bala C. Early Detection of Growth Hormone Secretagogue Receptor Antagonists Exploiting Their Atypical Behavior in Competitive Assays. Anal Chem 2019; 91:14812-14817. [PMID: 31702907 DOI: 10.1021/acs.analchem.9b03845] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
We report the proof-of-concept of a bioaffinity format designed for the early detection of growth hormone secretagogue receptor (GHS-R1a) antagonists in urine samples. We exploit here their atypical behavior in competitive experiments with labeled ghrelin (GHR), namely, the strong promoting effect on the GHR/GHS-R1a interaction at low molar ratios GHR/antagonist. The antagonists potentiate the GHR/GHS-R1a interaction, and they display the same effect on the interaction of GHS-R1a with other agonists listed as doping agents. The developed assay allows the estimation of affinity constants of ligand/receptor and antagonist/receptor binding and is amenable to optical, electrochemical, and mass-sensitive detection. The estimated affinity constants for GHR/GHS-R1a and antagonist/GHS-R1a in the absence of G proteins are in good agreement with recently reported data.
Collapse
Affiliation(s)
- George Madalin Danila
- Laboratory for Quality Control and Process Monitoring , University of Bucharest , 030018 Bucharest , Romania.,Romanian Doping Control Laboratory , 022103 Bucharest , Romania
| | - Mihaela Puiu
- Laboratory for Quality Control and Process Monitoring , University of Bucharest , 030018 Bucharest , Romania
| | - Lucian-Gabriel Zamfir
- Laboratory for Quality Control and Process Monitoring , University of Bucharest , 030018 Bucharest , Romania.,ICUB , University of Bucharest , 050107 Bucharest , Romania
| | - Camelia Bala
- Laboratory for Quality Control and Process Monitoring , University of Bucharest , 030018 Bucharest , Romania.,Department of Analytical Chemistry , University of Bucharest , 030018 Bucharest , Romania
| |
Collapse
|
4
|
Moldovan RP, Els-Heindl S, Worm DJ, Kniess T, Kluge M, Beck-Sickinger AG, Deuther-Conrad W, Krügel U, Brust P. Development of Fluorinated Non-Peptidic Ghrelin Receptor Ligands for Potential Use in Molecular Imaging. Int J Mol Sci 2017; 18:ijms18040768. [PMID: 28379199 PMCID: PMC5412352 DOI: 10.3390/ijms18040768] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2017] [Revised: 03/23/2017] [Accepted: 03/31/2017] [Indexed: 12/19/2022] Open
Abstract
The ghrelin receptor (GhrR) is a widely investigated target in several diseases. However, the current knowledge of its role and distribution in the brain is limited. Recently, the small and non-peptidic compound (S)-6-(4-bromo-2-fluorophenoxy)-3-((1-isopropylpiperidin-3-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4(3H)-one ((S)-9) has been described as a GhrR ligand with high binding affinity. Here, we describe the synthesis of fluorinated derivatives, the in vitro evaluation of their potency as partial agonists and selectivity at GhrRs, and their physicochemical properties. These results identified compounds (S)-9, (R)-9, and (S)-16 as suitable parent molecules for 18F-labeled positron emission tomography (PET) radiotracers to enable future investigation of GhrR in the brain.
Collapse
Affiliation(s)
- Rareş-Petru Moldovan
- Helmholtz-Zentrum Dresden-Rossendorf e. V., Institute of Radiopharmaceutical Cancer Research, 04318 Leipzig, Germany.
| | - Sylvia Els-Heindl
- Institute of Biochemistry, Universität Leipzig, 04103 Leipzig, Germany.
| | - Dennis J Worm
- Institute of Biochemistry, Universität Leipzig, 04103 Leipzig, Germany.
| | - Torsten Kniess
- Helmholtz-Zentrum Dresden-Rossendorf e. V., Institute of Radiopharmaceutical Cancer Research, 04318 Leipzig, Germany.
| | - Michael Kluge
- Department of Psychiatry, Universität Leipzig, 04103 Leipzig, Germany.
| | | | - Winnie Deuther-Conrad
- Helmholtz-Zentrum Dresden-Rossendorf e. V., Institute of Radiopharmaceutical Cancer Research, 04318 Leipzig, Germany.
| | - Ute Krügel
- Rudolf Boehm Institute of Pharmacology and Toxicology, Medical Faculty, Universität Leipzig, 04107 Leipzig, Germany.
| | - Peter Brust
- Helmholtz-Zentrum Dresden-Rossendorf e. V., Institute of Radiopharmaceutical Cancer Research, 04318 Leipzig, Germany.
| |
Collapse
|
5
|
Kong J, Chuddy J, Stock IA, Loria PM, Straub SV, Vage C, Cameron KO, Bhattacharya SK, Lapham K, McClure KF, Zhang Y, Jackson VM. Pharmacological characterization of the first in class clinical candidate PF-05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose-dependent insulin secretion ex vivo. Br J Pharmacol 2016; 173:1452-64. [PMID: 26784385 DOI: 10.1111/bph.13439] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2015] [Revised: 01/08/2016] [Accepted: 01/08/2016] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND AND PURPOSE Ghrelin increases growth hormone secretion, gastric acid secretion, gastric motility and hunger but decreases glucose-dependent insulin secretion and insulin sensitivity in humans. Antagonizing the ghrelin receptor has potential as a therapeutic approach in the treatment of obesity and type 2 diabetes. Therefore, the aim was to pharmacologically characterize the novel small-molecule antagonist PF-05190457 and assess translational pharmacology ex vivo. EXPERIMENTAL APPROACH Radioligand binding in filter and scintillation proximity assay formats were used to evaluate affinity, and europium-labelled GTP to assess functional activity. Rat vagal afferent firing and calcium imaging in dispersed islets were used as native tissues underlying food intake and insulin secretion respectively. KEY RESULTS PF-05190457 was a potent and selective inverse agonist on constitutively active ghrelin receptors and acted as a competitive antagonist of ghrelin action, with a human Kd of 3 nM requiring 4 h to achieve equilibrium. Potency of PF-05190457 was similar across different species. PF-05190457 increased intracellular calcium within dispersed islets and increased vagal afferent firing in a concentration-dependent manner with similar potency but was threefold less potent as compared with the in vitro Ki in recombinant overexpressing cells. The effect of PF-05190457 on rodent islets was comparable with glibenclamide, but glucose-dependent and additive with the insulin secretagogue glucagon-like peptide-1. CONCLUSIONS AND IMPLICATIONS Together, these data provide the pharmacological in vitro and ex vivo characterization of the first ghrelin receptor inverse agonist, which has advanced into clinical trials to evaluate the therapeutic potential of blocking ghrelin receptors in obesity and type 2 diabetes.
Collapse
Affiliation(s)
- J Kong
- Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA
| | - J Chuddy
- Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA
| | - I A Stock
- Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA
| | - P M Loria
- Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA
| | - S V Straub
- Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA
| | - C Vage
- Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA
| | - K O Cameron
- Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA
| | - S K Bhattacharya
- Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA
| | - K Lapham
- Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA
| | - K F McClure
- Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA
| | - Y Zhang
- Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA
| | - V M Jackson
- Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA
| |
Collapse
|
6
|
Ferro P, Gutiérrez-Gallego R, Bosch J, Farré M, Segura J. Fit-for-Purpose Radio Receptor Assay for the Determination of Growth Hormone Secretagogues in Urine. ACTA ACUST UNITED AC 2015; 20:1268-76. [DOI: 10.1177/1087057115594590] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2015] [Accepted: 06/14/2015] [Indexed: 12/27/2022]
Abstract
The everlasting pharmacological development is continuously producing new substances with potential doping abuse. Among these, secretagogues are very prone to misuse by athletes for their properties to release growth hormone (GH) and some limitations in the actual analytical methods to detect them. In this paper, an in-depth study on the key variables of the radio receptor method previously developed by our group is performed and a fit-for-purpose protocol is established. Thus, this sensitive and robust screening method is proposed as an intelligent and preventive antidoping method to detect new growth hormone secretagogues (GHSs) in exceptional suspicious urine samples obtained from athletes and will support the current detection methods based on liquid chromatography–mass spectrometry (LC-MS).
Collapse
Affiliation(s)
- P. Ferro
- Bioanalysis Research Group, Neuroscience Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - R. Gutiérrez-Gallego
- Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona Biomedical Research Park, Barcelona, Spain
- Anapharm Biotech, Barcelona, Spain
| | - J. Bosch
- Bioanalysis Research Group, Neuroscience Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - M. Farré
- Human Pharmacology and Neurosciences Research Group, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona–UAB, Cerdanyola del Vallés (Bellaterra), Spain
| | - J. Segura
- Bioanalysis Research Group, Neuroscience Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona Biomedical Research Park, Barcelona, Spain
| |
Collapse
|
7
|
Multiplexing Label-Free and Fluorescence-Based Methods for Pharmacological Characterization of GPCR Ligands. METHODS IN PHARMACOLOGY AND TOXICOLOGY 2015. [DOI: 10.1007/978-1-4939-2617-6_12] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
8
|
Evron T, Peterson SM, Urs NM, Bai Y, Rochelle LK, Caron MG, Barak LS. G Protein and β-arrestin signaling bias at the ghrelin receptor. J Biol Chem 2014; 289:33442-55. [PMID: 25261469 DOI: 10.1074/jbc.m114.581397] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The G protein-coupled ghrelin receptor GHSR1a is a potential pharmacological target for treating obesity and addiction because of the critical role ghrelin plays in energy homeostasis and dopamine-dependent reward. GHSR1a enhances growth hormone release, appetite, and dopamine signaling through G(q/11), G(i/o), and G(12/13) as well as β-arrestin-based scaffolds. However, the contribution of individual G protein and β-arrestin pathways to the diverse physiological responses mediated by ghrelin remains unknown. To characterize whether a signaling bias occurs for GHSR1a, we investigated ghrelin signaling in a number of cell-based assays, including Ca(2+) mobilization, serum response factor response element, stress fiber formation, ERK1/2 phosphorylation, and β-arrestin translocation, utilizing intracellular second loop and C-tail mutants of GHSR1a. We observed that GHSR1a and β-arrestin rapidly form metastable plasma membrane complexes following exposure to an agonist, but replacement of the GHSR1a C-tail by the tail of the vasopressin 2 receptor greatly stabilizes them, producing complexes observable on the plasma membrane and also in endocytic vesicles. Mutations of the contiguous conserved amino acids Pro-148 and Leu-149 in the GHSR1a intracellular second loop generate receptors with a strong bias to G protein and β-arrestin, respectively, supporting a role for conformation-dependent signaling bias in the wild-type receptor. Our results demonstrate more balance in GHSR1a-mediated ERK signaling from G proteins and β-arrestin but uncover an important role for β-arrestin in RhoA activation and stress fiber formation. These findings suggest an avenue for modulating drug abuse-associated changes in synaptic plasticity via GHSR1a and indicate the development of GHSR1a-biased ligands as a promising strategy for selectively targeting downstream signaling events.
Collapse
Affiliation(s)
| | | | | | - Yushi Bai
- From the Departments of Cell Biology
| | | | - Marc G Caron
- From the Departments of Cell Biology, Neurobiology, and Medicine, Duke University, Medical Center, Durham, North Carolina 27710
| | | |
Collapse
|
9
|
Khatib N, Gaidhane S, Gaidhane AM, Khatib M, Simkhada P, Gode D, Zahiruddin QS. Ghrelin: ghrelin as a regulatory Peptide in growth hormone secretion. J Clin Diagn Res 2014; 8:MC13-7. [PMID: 25302229 DOI: 10.7860/jcdr/2014/9863.4767] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2014] [Accepted: 06/12/2014] [Indexed: 12/19/2022]
Abstract
BACKGROUND Ghrelin is a type of growth hormone (GH) secretagogue that stimulates the release of GH. It is a first hormone linking gastrointestinal-pituitary axis. OBJECTIVE This review highlights the interaction of ghrelin with GHRH and somatostatin to regulate the secretion of GH and intends to explore the possible physiological role of the ghrelin-pituitary-GH axis linkage system. OBSERVATION Ghrelin is highly conserved among species and is classified into octanoylated (C8:0), decanoylated (C10:0), decenoylated (C10:1) and nonacylated,ghrelin. Acylated ghrelin is the major active form of human ghrelin. The primary production site of ghrelin is the stomach, and it interacts with stomach ghrelin as well as hypothalamic GHRH and somatostatin in the regulation of pituitary GH secretion. Ghrelin stimulate GH release through the GHS receptor to increase intracellular Ca2+ ([Ca2+] levels via IP3 signal transduction pathway. Ghrelin is a specific endogenous ligand for the GHS receptor and provides a definitive proof of the occurance of a GHS-GHS receptor signalling system in the regulation of GH secretion. CONCLUSION Studies suggests that ghrelin is a powerful pharmacological agent that exerts a potent, time-dependent stimulation of pulsatile secretion of GH.
Collapse
Affiliation(s)
- Nazli Khatib
- Associate Professor, Department of Physiology, Datta Meghe Institute of Medical Sciences , Sawangi (Meghe), Wardha, India
| | - Shilpa Gaidhane
- Assistant Professor, Department of Community Medicine, Datta Meghe Institute of Medical Sciences , Sawangi (Meghe), Wardha, India
| | - Abhay M Gaidhane
- Professor, Department of Community Medicine, J N Medical College, Datta Meghe Institute of Medical Sciences , Sawangi (Meghe), Wardha, India
| | - Mahanaaz Khatib
- Pharmacovigilance Co-ordinator, i3global , Pune Maharashtra, India
| | - Padam Simkhada
- Senior Lecturer, International Health School of Health and Related Research (ScHARR),University of Sheffield , UK
| | - Dilip Gode
- Vice Chancellor, Datta Meghe Institute of Medical Sciences , Sawangi (Meghe), Wardha, India
| | - Quazi Syed Zahiruddin
- Associate Dean, Professor, Department of Community Medicine, Datta Meghe Institute of Medical Sciences , Sawangi (Meghe), Wardha, India
| |
Collapse
|
10
|
Callaghan B, Furness JB. Novel and Conventional Receptors for Ghrelin, Desacyl-Ghrelin, and Pharmacologically Related Compounds. Pharmacol Rev 2014; 66:984-1001. [DOI: 10.1124/pr.113.008433] [Citation(s) in RCA: 81] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
|
11
|
Cameron KO, Bhattacharya SK, Loomis AK. Small Molecule Ghrelin Receptor Inverse Agonists and Antagonists. J Med Chem 2014; 57:8671-91. [DOI: 10.1021/jm5003183] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Affiliation(s)
- Kimberly O. Cameron
- Worldwide
Medicinal Chemistry, Pfizer Worldwide Research and Development, 610
Main Street, Cambridge, Massachusetts 02139, United States
| | - Samit K. Bhattacharya
- Worldwide
Medicinal Chemistry, Pfizer Worldwide Research and Development, 610
Main Street, Cambridge, Massachusetts 02139, United States
| | - A. Katrina Loomis
- Pharmatherapeutics
Precision Medicine, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
12
|
Bhattacharya SK, Andrews K, Beveridge R, Cameron KO, Chen C, Dunn M, Fernando D, Gao H, Hepworth D, Jackson VM, Khot V, Kong J, Kosa RE, Lapham K, Loria PM, Londregan AT, McClure KF, Orr STM, Patel J, Rose C, Saenz J, Stock IA, Storer G, VanVolkenburg M, Vrieze D, Wang G, Xiao J, Zhang Y. Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate. ACS Med Chem Lett 2014; 5:474-9. [PMID: 24900864 DOI: 10.1021/ml400473x] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2013] [Accepted: 02/18/2014] [Indexed: 01/15/2023] Open
Abstract
The identification of potent, highly selective orally bioavailable ghrelin receptor inverse agonists from a spiro-azetidino-piperidine series is described. Examples from this series have promising in vivo pharmacokinetics and increase glucose-stimulated insulin secretion in human whole and dispersed islets. A physicochemistry-based strategy to increase lipophilic efficiency for ghrelin receptor potency and retain low clearance and satisfactory permeability while reducing off-target pharmacology led to the discovery of 16h. Compound 16h has a superior balance of ghrelin receptor pharmacology and off-target selectivity. On the basis of its promising pharmacological and safety profile, 16h was advanced to human clinical trials.
Collapse
Affiliation(s)
- Samit K. Bhattacharya
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Kim Andrews
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Ramsay Beveridge
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Kimberly O. Cameron
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Chiliu Chen
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Matthew Dunn
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Dilinie Fernando
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Hua Gao
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - David Hepworth
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - V. Margaret Jackson
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Vishal Khot
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Jimmy Kong
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Rachel E. Kosa
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Kimberly Lapham
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Paula M. Loria
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Allyn T. Londregan
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Kim F. McClure
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Suvi T. M. Orr
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Jigna Patel
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Colin Rose
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - James Saenz
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Ingrid A. Stock
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Gregory Storer
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Maria VanVolkenburg
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Derek Vrieze
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Guoqiang Wang
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Jun Xiao
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Yingxin Zhang
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
13
|
Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ. The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 2013; 170:1459-581. [PMID: 24517644 PMCID: PMC3892287 DOI: 10.1111/bph.12445] [Citation(s) in RCA: 505] [Impact Index Per Article: 45.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
The Concise Guide to PHARMACOLOGY 2013/14 provides concise overviews of the key properties of over 2000 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.12444/full. G protein-coupled receptors are one of the seven major pharmacological targets into which the Guide is divided, with the others being G protein-coupled receptors, ligand-gated ion channels, ion channels, catalytic receptors, nuclear hormone receptors, transporters and enzymes. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. A new landscape format has easy to use tables comparing related targets. It is a condensed version of material contemporary to late 2013, which is presented in greater detail and constantly updated on the website www.guidetopharmacology.org, superseding data presented in previous Guides to Receptors and Channels. It is produced in conjunction with NC-IUPHAR and provides the official IUPHAR classification and nomenclature for human drug targets, where appropriate. It consolidates information previously curated and displayed separately in IUPHAR-DB and the Guide to Receptors and Channels, providing a permanent, citable, point-in-time record that will survive database updates.
Collapse
Affiliation(s)
- Stephen PH Alexander
- School of Life Sciences, University of Nottingham Medical SchoolNottingham, NG7 2UH, UK
| | - Helen E Benson
- The University/BHF Centre for Cardiovascular Science, University of EdinburghEdinburgh, EH16 4TJ, UK
| | - Elena Faccenda
- The University/BHF Centre for Cardiovascular Science, University of EdinburghEdinburgh, EH16 4TJ, UK
| | - Adam J Pawson
- The University/BHF Centre for Cardiovascular Science, University of EdinburghEdinburgh, EH16 4TJ, UK
| | - Joanna L Sharman
- The University/BHF Centre for Cardiovascular Science, University of EdinburghEdinburgh, EH16 4TJ, UK
| | | | - John A Peters
- Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of DundeeDundee, DD1 9SY, UK
| | - Anthony J Harmar
- The University/BHF Centre for Cardiovascular Science, University of EdinburghEdinburgh, EH16 4TJ, UK
| |
Collapse
|
14
|
Verspohl EJ. Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes. Pharmacol Rev 2012; 64:188-237. [DOI: 10.1124/pr.110.003319] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
|
15
|
Delporte C. Recent advances in potential clinical application of ghrelin in obesity. J Obes 2012; 2012:535624. [PMID: 22523666 PMCID: PMC3317165 DOI: 10.1155/2012/535624] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/17/2011] [Accepted: 12/04/2011] [Indexed: 02/07/2023] Open
Abstract
Ghrelin is the natural ligand of the growth hormone secretagogue receptor (GHS-R1a). Ghrelin is a 28 amino acid peptide possessing a unique acylation on the serine in position 3 catalyzed by ghrelin O-acyltransferase (GOAT). Ghrelin stimulates growth hormone secretion, but also appetite, food intake, weight gain, and gastric emptying. Ghrelin is involved in weight regulation, obesity, type 2 diabetes, and metabolic syndrome. Furthermore, a better understanding of ghrelin biology led to the identification of molecular targets modulating ghrelin levels and/or its biological effects: GOAT, ghrelin, and GHS-R1a. Furthermore, a recent discovery, showing the involvement of bitter taste receptor T2R in ghrelin secretion and/or synthesis and food intake, suggested that T2R could represent an additional interesting molecular target. Several classes of ghrelin-related pharmacological tools for the treatment of obesity have been or could be developed to modulate the identified molecular targets.
Collapse
Affiliation(s)
- Christine Delporte
- Laboratory of Biological Chemistry and Nutrition, Faculty of Medicine, Université libre de Bruxelles, 1070 Brussels, Belgium
- *Christine Delporte:
| |
Collapse
|
16
|
Pinyot A, Nikolovski Z, Bosch J, Such-Sanmartín G, Kageyama S, Segura J, Gutiérrez-Gallego R. Growth hormone secretagogues: out of competition. Anal Bioanal Chem 2011; 402:1101-8. [DOI: 10.1007/s00216-011-5544-8] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2011] [Revised: 10/11/2011] [Accepted: 10/27/2011] [Indexed: 10/15/2022]
|
17
|
Inoue H, Sakamoto Y, Kangawa N, Kimura C, Ogata T, Fujieda K, Qian ZR, Sano T, Itakura M. Analysis of expression and structure of the rat GH-secretagogue/ghrelin receptor (Ghsr) gene: roles of epigenetic modifications in transcriptional regulation. Mol Cell Endocrinol 2011; 345:1-15. [PMID: 21756973 DOI: 10.1016/j.mce.2011.06.034] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/13/2011] [Revised: 06/03/2011] [Accepted: 06/28/2011] [Indexed: 11/23/2022]
Abstract
In the current study, to elucidate the molecular basis of cell type-specific expression of the GH-secretagogue/ghrelin receptor type 1A (GHSR1A), we characterized the structure and putative promoter region of the rat Ghsr gene. We identified an alternative 5'-untranslated first exon that contains multiple transcription start sites, and confirmed a 200-bp sequence proximal to this exon to be sufficient for basal promoter activity. A promoter-associated CpG island conserved across different species was found to be hypomethylated in Ghsr1a-expressing cell lines, while being heavily methylated in non-expressing cells. In cells with low or absent Ghsr1a expression, treatment with demethylating agents activated Ghsr1a transcription. Chromatin immunoprecipitation assays demonstrated Ghsr1a-expressing cells to display active histone modifications, whereas repressive modifications were present exclusively in other cell types. These results suggest epigenetic modifications at GHSR to play important roles in determining GHSR1A expression and abundance, and therefore the consequent sensitivity of cells to ghrelin.
Collapse
Affiliation(s)
- Hiroshi Inoue
- Diabetes Therapeutics and Research Center, The University of Tokushima, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Sabbatini FM, Melotto S, Bernasconi G, Bromidge SM, D'Adamo L, Rinaldi M, Savoia C, Mundi C, Di Francesco C, Zonzini L, Costantini VJA, Perini B, Valerio E, Pozzan A, Perdonà E, Visentini F, Corsi M, Di Fabio R. Azabicyclo[3.1.0]hexane-1-carbohydrazides as Potent and Selective GHSR1a Ligands Presenting a Specific in vivo Behavior. ChemMedChem 2011; 6:1981-5. [DOI: 10.1002/cmdc.201100285] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2011] [Revised: 07/17/2011] [Indexed: 11/07/2022]
|
19
|
Costantini VJA, Vicentini E, Sabbatini FM, Valerio E, Lepore S, Tessari M, Sartori M, Michielin F, Melotto S, Bifone A, Pich EM, Corsi M. GSK1614343, a novel ghrelin receptor antagonist, produces an unexpected increase of food intake and body weight in rodents and dogs. Neuroendocrinology 2011; 94:158-68. [PMID: 21778696 DOI: 10.1159/000328968] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/12/2010] [Accepted: 04/27/2011] [Indexed: 12/14/2022]
Abstract
Ghrelin is a 28-amino-acid polypeptide expressed in the stomach and hypothalamus that stimulates GH secretion, increases food intake (FI) and promotes body weight (BW) gain most likely via activation of the growth hormone secretagogue receptor type 1a (GHSR1a). GSK1614343 is a novel selective and potent GHSR antagonist with no partial agonist properties, recently characterized as GH secretion inhibitor by Sabbatini et al. [Chem Med Chem 2010;5:1450-1455]. In the present study, GSK1614343 (10 mg/kg) was not able to antagonize ghrelin-induced food consumption in rat, but unexpectedly stimulated FI and BW gain in both rats and dogs, a profile associated with decreased ghrelin plasma level. Interestingly, GSK1614343 selectively reduced the pro-opiomelanocortin mRNA levels in rat hypothalami chronically treated with the compound. To better understand the observed effects, we administered GSK1614343 (30 mg/kg) to Ghsr null mice and measured body mass components (fat, lean and free fluid) by using a NMR spectrometer. The increases of FI and BW were abolished in Ghsr null mice, while fat and lean masses increased in wild-type mice. Taken together, these results indicate that the orexigenic effect of GSK1614343 is mediated by GHSR1a and that the weight gain could be attributed to the increase of both adiposity and muscle mass, but not to fluid retention. The observed dissociation between effects on GH secretion and effects on FI/BW is inconsistent with a simple hormone-receptor model, suggesting unknown underlying regulations of the ghrelin system whose understanding require further investigation.
Collapse
|